Denosumab a new treatment for postmenopausal osteoporosis

Christopher J. Yates; Peter R. Ebeling

Denosumab a new treatment for postmenopausal osteoporosis

Research output: Contribution to journal › Short Survey › Other › peer-review

Abstract

Denosumab (Prolia) is a promising new first-line agent for the treatment of postmenopausal osteoporosis with proven fracture risk reduction.

Original language	English
Pages (from-to)	61-63
Number of pages	3
Journal	Medicine Today
Volume	12
Issue number	6
Publication status	Published - Jun 2011
Externally published	Yes

Cite this

@article{d258f7003c1a42d3b9fdc9b60a98c3ae,

title = "Denosumab a new treatment for postmenopausal osteoporosis",

abstract = "Denosumab (Prolia) is a promising new first-line agent for the treatment of postmenopausal osteoporosis with proven fracture risk reduction.",

author = "Yates, {Christopher J.} and Ebeling, {Peter R.}",

year = "2011",

month = jun,

language = "English",

volume = "12",

pages = "61--63",

journal = "Medicine Today",

issn = "1443-430X",

publisher = "Medicine Today",

number = "6",

}

TY - JOUR

T1 - Denosumab a new treatment for postmenopausal osteoporosis

AU - Yates, Christopher J.

AU - Ebeling, Peter R.

PY - 2011/6

Y1 - 2011/6

N2 - Denosumab (Prolia) is a promising new first-line agent for the treatment of postmenopausal osteoporosis with proven fracture risk reduction.

AB - Denosumab (Prolia) is a promising new first-line agent for the treatment of postmenopausal osteoporosis with proven fracture risk reduction.

UR - http://www.scopus.com/inward/record.url?scp=79959922906&partnerID=8YFLogxK

M3 - Short Survey

AN - SCOPUS:79959922906

SN - 1443-430X

VL - 12

SP - 61

EP - 63

JO - Medicine Today

JF - Medicine Today

IS - 6

ER -

Denosumab a new treatment for postmenopausal osteoporosis

Abstract

Other files and links

Cite this